Nasdaq
$0.4284▲ 3.88%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $355,111.04Shares out 0.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
70- 10.14Pre-market26.10.14 21:306-KKey event#●●●#●●●#●●●
Biodexa Pharmaceuticals PlcBullish
Biodexa Pharmaceuticals has successfully enrolled 100 patients in its registrational Phase 3 'Serenta' trial for eRapa in Familial Adenomatous Polyposis (FAP). Based on current recruitment rates, the pre-specified futility analysis is expected early next year, with the database lock anticipated around the end of next year, both occurring significantly sooner than originally planned.…more
$0.4284+3.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Pre-market26.10.14 09:33filed424B3Offering
Biodexa Pharmaceuticals Plc
Final prospectus filed (supplement format).
$0.4284+3.88%vs prev closeView filingShare - 10.14Pre-market26.10.14 09:33filed424B3Offering
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals announced a change in its American Depositary Shares (ADS) ratio from 1:50 to 1:400, effective on or about October 26, 2026. This change will require ADS holders to exchange 8 old ADSs for 1 new ADS, effectively functioning as a 1-for-8 reverse ADS split.…more
$0.4284+3.88%vs prev closeView filingShare
69 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 21:30#●●●#●●●#●●●
Biodexa Reaches 100-Patient Milestone in Phase 3 FAP Trial
Biodexa Pharmaceuticals has enrolled 100 patients in its registrational Phase 3 'Serenta' trial for the FAP treatment eRapa. The company expects the trial's futility analysis and database lock to occur earlier than originally anticipated due to strong recruitment performance.…more
$0.4284+3.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.8After-hours26.10.09 05:13
●●●●●●●● ●●●●● ●●●●●●
Biodexa announced a change in its ADS ratio to one ADS per 400 ordinary shares. This adjustment is expected to become effective on October 26.…more
$0.4284+3.88%vs prev closeShareBenzinga - 9.15Pre-market26.09.15 21:02
●●●●●●●● ●●●●● ●●●●●●
Biodexa Pharmaceuticals has entered into a warrant exercise agreement to raise approximately $2.3 million in gross proceeds. The company also issued new five-year warrants, which introduces potential future share dilution.…more
$0.4284+3.88%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report